Kacie Peters and Erik Stanley are extraordinary. Despite dual, concurrent diagnoses with stage IV colorectal cancer, they have risen to the challenges posed by this disease and continue to be incredible parents, accomplished professionals, and now, outspoken advocates for colorectal cancer.
A clinical trial out of Memorial Sloan Kettering Cancer Center has set the cancer community abuzz after it showed a 100 percent success rate among the first 14 participants who completed treatment.
Dr. John Marshall, Chief of the Division of Hematology/Oncology at Medstar Georgetown University Hospital, joins the Alliance to answer common questions about the COVID-19 vaccines among the colon cancer and rectal cancer patient population.
I was a healthy 38-year-old woman who was a vegetarian, didn't really drink, didn't smoke, and was in pretty good shape. Now, I was sitting on my bathroom floor having just thrown up the CT contrast.
Open surgery is the most common type of surgery in the United States. But given advancements in surgical technology, it may not be the best thing for all patients. The good news is colorectal patients may have other minimally invasive surgical options.
While minimally invasive surgery has been shown to be as safe as open surgery, the recovery is expected to be faster and the risk of infection following surgery is smaller.
Susan Burke’s journey with colorectal cancer started with an appendectomy. At 47 years old, a pain in her right, lower abdomen for more than a year led doctors to find an appendix that was swollen to three times its normal size.
This new technology could refine the prognosis of stage II and some low-risk stage III colon cancer patients and provide doctors with additional information when making decisions about chemotherapy treatment.
The U.S. Food and Drug Administration has approved encorafenib (marketed as BRAFTOVI) in combination with cetuximab (marketed as ERBITUX) as a second-line therapy for the treatment of adult patients with metastatic colorectal cancer with a BRAFV600E mutation.
Surgery is considered the most common treatment for early stage or resectable (removable) colorectal cancers. Doctors will evaluate which type of surgery is best for a patient, depending on the extent of the tumor, where it is located. The three main types of surgery for colorectal cancer are open, laparoscopic, and robotic.
Minimally invasive surgery (MIS) has gained popularity since its introduction. MIS can be performed in patients with colorectal cancer to achieve a variety of outcomes, including the removal of a portion of the colon, removal of the entire colon, creating an ostomy, or reconnecting and reconstructing the colon.
The use of minimally invasive surgery (MIS) in colorectal surgery has been increasing in recent years. Multiple studies have shown that when appropriate, MIS procedures are as safe as open surgeries.
Colorectal cancer is the one of the most common malignancies affecting both men and women. Surgery is the main treatment for resectable colorectal cancer and especially for patients diagnosed in early stages. During surgery, the section of the colon that harbors the tumor alongside the surrounding healthy tissue and nearby lymph nodes are removed.
Merck's Keytruda has been approved by the FDA for patients with a microsatellite instability-high (also known as MSI-H) or a mismatch repair deficient (dMMR) biomarker following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.
If you or a loved one have recently been diagnosed with colorectal cancer that has metastasized to the liver, it is important to understand the options for treatment.
If there is one common theme in all of the literature and scientific papers, it is that cannabis and cannabinoids enhance the benefits of conventional treatment for side effect management.